Grioni Matteo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7147708/publications.pdf

Version: 2024-02-01

26 papers	1,697 citations	361413 20 h-index	642732 23 g-index
26 all docs	26 docs citations	26 times ranked	3043 citing authors

#	Article	IF	Citations
1	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Research, 2012, 72, 2746-2756.	0.9	470
2	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 2018, 9, 4832.	12.8	144
3	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science, 2021, 374, 216-224.	12.6	135
4	Targeting TNF-Î± to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. Journal of Immunology, 2012, 188, 2687-2694.	0.8	128
5	Tenascin-C Protects Cancer Stemâ€“like Cells from Immune Surveillance by Arresting T-cell Activation. Cancer Research, 2015, 75, 2095-2108.	0.9	112
6	Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunology, 2009, 10, 1.	2.2	79
7	Peripheral T?cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. European Journal of Immunology, 2005, 35, 66-75.	2.9	78
8	Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. Frontiers in Immunology, 2020, 11, 565470.	4.8	63
9	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. Cell Reports, 2018, 22, 3006-3020.	6.4	62
10	iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells. PLoS ONE, 2010, 5, e8646.	2.5	61
11	Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells. Cancer Research, 2008, 68, 292-300.	0.9	59
12	Vasculatureâ€targeted tumor necrosis factorâ€alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate, 2008, 68, 1105-1115.	2.3	47
13	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. Clinical Cancer Research, 2018, 24, 2171-2181.	7.0	40
14	Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. OncoImmunology, 2013, 2, e24520.	4.6	38
15	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFÎ± Expression and Empower Adoptive Cell Therapy for Solid Tumors. Cancer Research, 2017, 77, 658-671.	0.9	30
16	Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer. Clinical Cancer Research, 2011, 17, 1012-1023.	7.0	29
17	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. OncoImmunology, 2015, 4, e1008850.	4.6	27
18	Concomitant Tumor and Minor Histocompatibility Antigenâ€“Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors. Cancer Research, 2010, 70, 3505-3514.	0.9	25

#	Article	IF	Citations
19	Type 2 Cytotoxic T Lymphocytes Modulate the Activity of Dendritic Cells Toward Type 2 Immune Responses. Journal of Immunology, 2006, 177, 2131-2137.	0.8	21
20	Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated From Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human Tumors. Stem Cells Translational Medicine, 2013, 2, 678-689.	3.3	20
21	Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings. Cancer Research, 2013, 73, 3545-3554.	0.9	17
22	Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic Tâ€„lymphocytes. European Journal of Immunology, 2006, 36, 3157-3166.	2.9	6
23	Boosting anticancer vaccines. OncoImmunology, 2013, 2, e25032.	4.6	6
24	Abstract A83: Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in Vk*MYC mice.. , 2013, , .		0
25	Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans. Blood, 2014, 124, 5678-5678.	1.4	0
26	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. Blood, 2019, 134, 683-683.	1.4	0